Table 3.
Sofosbuvir-based regimens according to HCV genotype and date of FDA approval
| Regimen | Expected FDA approval date |
|---|---|
| HCV-1 | |
| IFN sparing | |
| • SOF + PegIFN/Rbv 12 weeks | 2014 |
| IFN free | |
| • SOF + DCV 12/24 weeks | 2015 (off-label) |
| • SOF + LDV 8/12 weeks | 2015 |
| • SOF + SMV 12/24 weeks | 2014 (off-label) |
| HCV-2/3 | |
| IFN free | |
| • SOF + Rbv 12 weeks (HCV-3: 16/24 weeks) | 2014 |
| • SOF + PegIFN/Rbv 12 weeks (HCV-3 only) | 2014 |
| HCV-4 | |
| IFN sparing | |
| • SOF + PegIFN/Rbv 12 weeks | 2014 |
| IFN free | |
| • SOF + Rbv 12/24 weeks | 2014 (off-label) |
Abbreviations: DCV, daclatasvir; FDA, US Food and Drug Administration; HCV, hepatitis C virus; LDV, ledipasvir; PegIFN, Peginterferon; Rbv, ribavirin; SOF, sofosbuvir; SMV, simeprevir.